Marker Therapeutics (MRKR) announced that the Company has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas, CPRIT, to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRKR: